Clinical trials: Post-surgical Ocular Inflammation
- Condition Post-surgical Ocular Inflammation
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Cataract
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
- Trial name
- NCT00870103
- Testing
- Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Post Surgical Ocular Inflammation
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
- Trial name
- NCT04222725
- Testing
- TRS01 eye drops
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Tarsier Pharma
Ocular Inflammation and Pain After Cataract Surgery
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04810962
- Testing
- APP13007, 0.05%
- Where
- 31 sites in United States
- Volunteers
- 370 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Ocular Inflammation and Pain
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04739709
- Testing
- APP13007, 0.05%
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 378 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataract
A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery
This is a safety and efficacy study of a Dexamethasone Drug Delivery System for anterior segment inflammation and pain following cataract extraction with lens implantation.
- Trial name
- NCT01605942
- Testing
- Dexamethasone Drug Delivery System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Allergan
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Ocular Inflammation
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers
The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in topical administration of differing dosing regimens of ISV-303 compared to vehicle and Xibrom™ when dosed for 2 weeks in…
- Trial name
- NCT01190878
- Testing
- ISV-303, DuraSite Vehicle, Xibrom™
- Volunteers
- 169 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Post Ocular Surgical Inflammation and Pain
Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and pain in subjects who have undergone…
- Trial name
- NCT02034019
- Testing
- Dexamethasone, Punctum Plug
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation, Cataract
A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery
This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.
- Trial name
- NCT06497699
- Testing
- Dexycu
- Where
- 2 sites in China
- Volunteers
- 263 people
- Sponsor
- Ocumension Therapeutics (Shanghai) Co., Ltd
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a…
- Trial name
- NCT04324359
- Testing
- SURF-201
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Surface Ophthalmics, Inc.
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02736175
- Testing
- Dexamethasone
- Volunteers
- 438 people
- Sponsor
- Ocular Therapeutix, Inc.
Cataract
Confirmatory Study Nepafenac 0.3%
The purpose of this study was to assess the safety and efficacy of an investigational eye drop intended for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
- Trial name
- NCT01109173
- Testing
- Nepafenac Ophthalmic Suspension, 0.3%, Nepafenac Ophthalmic Suspension, 0.1%, Nepafenac Ophthalmic Suspension 0.3% Vehicle
- Where
- United States
- Volunteers
- 2,120 people
- Sponsor
- Alcon Research
Inflammation
Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery
This is a multicenter, double-masked, randomized, vehicle-controlled, parallel-comparison study conducted at sites in the United States (US) in subjects undergoing routine unilateral cataract extraction and lens replacement…
- Trial name
- NCT06164743
- Testing
- VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- VivaVision Biotech, Inc
Cataracts, Inflammation
Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery
The primary objective of this study was to compare the safety and efficacy of Durezol™ compared to Pred Forte™ for the treatment of inflammation following cataract surgery in a pediatric population 0 to 3 years of age.
- Trial name
- NCT01124045
- Testing
- Difluprednate ophthalmic emulsion, 0.05%, Prednisolone acetate ophthalmic suspension, 1.0%
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Alcon Research
Inflammatory Reaction Due to Ocular Lens Prosthesis
Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery
This study will test the efficacy and safety of IBI-10090 for the reduction of ocular inflammation after cataract surgery.
- Trial name
- NCT01048593
- Testing
- IBI-10090
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- ICON Bioscience Inc